Maryam Lustberg, MD, MPH, Appointed Director of The Breast Center and Chief of Breast Medical Oncology

We are pleased to announce Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as an Associate Professor of Medicine (Medical Oncology). Dr. Lustberg joins Yale from The Ohio State University where she is an Associate Professor in the Division of Medical Oncology at The James, Director of their Breast Cancer Survivorship Program, and Medical Director of Supportive Care. She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of “Regional Top Doctors,” and “Exceptional Women in Medicine” for 2020. She is currently participating in the American Society of Clinical Oncology (ASCO) Leadership Development Program.

With an emphasis on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment, Dr. Lustberg will continue her research efforts at Yale. She is also focused on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She is an NCI-funded investigator and active in both ALLIANCE and SWOG Cancer Cooperative Groups. Dr. Lustberg collaborates widely with researchers from around the world, thriving in creating innovative multidisciplinary scientific teams. Her mentorship has been recognized by numerous awards including Best Teacher Award by Hematology Oncology Fellows and the Shining Star Award for Medical Student Mentorship.
Nationally, Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is actively engaged in national patient advocacy organizations with a focus on improving shared decision making and increasing patient engagement in clinical trials. In addition, she serves as the President Elect and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship. In the last decade, she has published over 140 peer-reviewed publications and book chapters.

Dr. Lustberg received her medical degree from the University of Maryland where she also completed her residency and went on to complete a fellowship in medical oncology and in breast medical oncology at The Ohio State University before joining the faculty in 2010. She earned a Master’s in Public Health from The Ohio State University in 2013.

**U.S. News Best Hospitals Voting**
We need your support to move our reputation score higher in U.S. News & World Report’s annual Best Hospital’s Guide. Please support the outstanding cancer research and patient care you provide each day by participating in this year’s survey.

Online voting for reputation scores is opening through Doximity and will be fully available next week to all registered providers. When you receive an email from support@Doximity.com inviting you to participate, please take a few minutes to vote and support cancer services at Smilow Cancer Hospital. When making your selection, you can type Smilow or Yale and Smilow Cancer Hospital at Yale New Haven (New Haven, CT) will appear for you to select.

**Grant Announced to Address Cancer Health Inequities**
Biotechnology company Genentech, a member of the Roche Group, has awarded a research grant to Yale Cancer Center and Smilow Cancer Hospital to measure, address, and create accountability around cancer health inequities. The 2-year, $750k award will fund a partnership between The Equity Research and Innovation Center (ERIC) at Yale School of Medicine and the Center for Community Engagement and Health Equity (CEHE) at Yale Cancer Center and Smilow Cancer Hospital to embed a health equity framework into SCH’s current quality measurement program.

Grant goals include the identification of high impact equity sensitive measures along the cancer care continuum and to stratify SCH data by race, ethnicity, and language to identify health inequities within these measures. Researchers also hope to develop both an internal and community facing Health Equity and Quality Dashboard that displays SCH specific quality data and performance improvement goals for a new health equity measure portfolio.

Learn More
Notables

Joan Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry, and a Howard Hughes Medical Institute investigator, has been named a Wolf Prize Laureate in Medicine for 2021 by the Israel-based Wolf Foundation. The foundation is honoring Dr. Steitz for her many fundamental contributions to the field of RNA biology. In particular, the Foundation notes her discovery of the critical roles of small non-coding RNAs, which laid the foundation for much of the subsequent research on RNA splicing. The use of RNA-based vaccines in the battle against COVID-19 builds on Professor Steitz’s pioneering work.

Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Disease Aligned Research Team Leader for the Head & Neck Cancers Program, and Co-Leader of the Developmental Therapeutics Research Program, will co-chair the NCI Clinical Trial Planning Meeting on TP53 Mutated Head and Neck Cancer this weekend. In addition, on March 3-4, she will co-chair the FDA Project 2025 Symposium on Locally Advanced Head and Neck Cancer.

Craig Crews, PhD, American Cancer Society Professor, John C. Malone Professor of Molecular, Cellular, and Developmental Biology, has been awarded the Scheele Award from the Swedish Pharmaceutical Society in recognition of excellence in drug development and discovery.

Prasanna Ananth, MD, MPH, Assistant Professor of Pediatrics (Hematology/Oncology) has received an award for submitting one of the Top Scoring Abstracts for the 2021 National Comprehensive Cancer Network (NCCN) Virtual Annual Conference. Dr. Ananth will be presenting an oral poster presentation on Saturday, March 20, 11am-12:15pm.

Greenwich Hospital recently presented its 2020 Breast Center Award to all Greenwich Hospital employees and families in honor of their valiant ongoing efforts during the global COVID-19 pandemic. The award is granted annual to a member of the community or hospital team in special recognition of a substantial contribution to the Breast Program at Greenwich Hospital and Smilow Cancer Hospital Care Center at Greenwich.

Smita Krishnaswamy, PhD, Associate Professor of Genetics and Computer Science, has been awarded a two-year, $75,000 Sloan Research Fellowship to advance her work.

Congratulations to Wajih Kidwai, MD, FACP, promoted to Associate Professor of Clinical Medicine (Medical Oncology), Kert Sabbath, MD, FACP, promoted to Associate Professor of Clinical Medicine (Medical Oncology), and Robert Legare, MD, FACP, who has been appointed to Associate Professor of Clinical Medicine (Medical Oncology).

Join Smilow Cancer Hospital on Facebook

Congratulations to Valentina Greco, PhD, Carolyn Walch Slayman Professor of Genetics, recipient of the 2021 Momentum Award from the International Society for Stem Cell Research! The award recognizes the exceptional achievements of an investigator whose innovative research has established a major area of stem cell-related research with a strong trajectory for future success.

Read More

Michaela Dinan, PhD, newly appointed Co-Leader of Yale Cancer Center's Cancer Prevention and Control Research Program, recently joined Yale Cancer Answers on Connecticut Public Radio, WNPR, to discuss Cancer Prevention in honor of February's Cancer Prevention Awareness Month. Dr. Dinan's research focuses on kidney cancer outcomes and prevention.

Read More
Employee Profile: Chivonne Pullen

Chivonne Pullen came to Yale nearly 14 years ago, long after serving in the Marine Corps, and started in telecommunications when it was mostly managing pagers and landlines. Since that time, her role has changed and for the last seven years she has been a Mobile Device Analyst for all of Yale New Haven Health System. As part of the “Tech Deck” she oversees the distribution, set-up, and maintenance of thousands of devices and cellular lines.

When COVID hit and many people moved to remote work stations, Chivonne came into the office every day to make sure work could continue and people were able to connect with their cellular devices remotely. She handles walk-ins, as well as remote set-up, which can be challenging when she needs to explain things over the phone. “It takes patience on both sides,” said Chivonne. “I walk people through step by step as best I can and make sure they have what they need. I miss the face to face interactions, but we are always ready for anything.”

Chivonne manages hundreds of visits and calls weekly and commented that it takes everyone working together to fulfill the mission of quality patient care. Carolyn Truini, BA, MCHL, OPN-CG, Coordinator for Smilow Cancer Hospital’s Department of Operations, commented, “Chivonne has a high aptitude for mobile devices and has assisted doctors, administrators, and staff with their mobile devices. The Tech Deck deploys all devices and when there is a roll out of new devices, it is a huge undertaking. They are responsible for loading all the numerous applications on to YNHH mobile phones, MHB phones, and iPads. Chivonne and the entire staff does this with an abundance of aptitude and an incredible customer service attitude.” Thank you to Chivonne and the entire team for keeping Smilow Cancer Hospital connected!

Recent Publications


Happy Valentine’s Day from all of us at Smilow Cancer Hospital and Yale Cancer Center. Thank you to each and every one of our healthcare heroes who continually go above and beyond for our patients and their families!

Our annual Ruth McCorkle Advanced Practice Provider Award was recently presented by Kim Slusser, MSN, RN, CHPN, NEA-BC, Vice President of Patient Services at Smilow Cancer Hospital, and Vanna Dest, APRN, Senior Program Manager for Advanced Practice at Smilow Cancer Hospital.

Vanna began by sharing reflections of Ruth, the “Godmother of Oncology Nursing,” who recognized the importance and contributions of APPs. Kim continued by announcing this year’s award winner, Jacqueline Dibble, FNP-BC, APRN, an advanced practice provider with the Smilow Cancer Hospital.

Read More


Read More


Read More


Read More


Read More


Read More

Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR (2021) We are proud of our Yale Medical Oncology-Hematology Fellowship Program, directed by Alfred Lee, MD, PhD, which provides promising young physicians a wealth of clinical and research opportunities to advance their careers. Learn more about the opportunities our fellows have, and how they impact patient care at Smilow Cancer Hospital: https://bit.ly/36nzl9A
PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors
*Nature Reviews Clinical Oncology*, Online ahead of print.
Read More

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Read More

Targeting IL-21 to Tumor-Reactive T Cells Enhances Memory T Cell Responses and Anti-PD-1 Antibody Therapy
*Nature Communications.*
Read More

Read More

Yap TA, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria JC, Plummer R, de Bono JS, Tabernero J, Banerji U (2021)
SARS-Cov-2 Vaccination and Phase 1 Cancer Clinical Trials
*The Lancet Oncology*, Online ahead of print.
Read More

Molecular Medicine Tumor Board: Whole-Genome Sequencing to Inform on Personalized Medicine for a Man with Advanced Prostate Cancer
*Prostate Cancer and Prostatic Diseases*, Online ahead of print.
Read More

Mutant-selective Degradation by BRAF-targeting PROTACs
*Nature Communications.*
Read More

Bircher JE, Koleske AJ (2021)
Trio Family Proteins as Regulators of Cell Migration and Morphogenesis in Development and Disease - Mechanisms and Cellular Contexts
*Journal of Cell Science.*
Read More

Interested in sharing what quality of life means to you? The Rising Tide Foundation is launching an international Patient Art Exhibition and is looking for submissions from cancer survivors in any art form that communicates imagination, conceptual ideas, or technical skill, intended to communicate truths about each person’s particular story through art. Submit your work now!

Yale Cancer Center is one of only 51 Comprehensive Cancer Centers in the country designated by the National Cancer Institute. Dr. Charles Fuchs discusses the significance of this designation and the profound implications it has for those who choose Yale as the place they will be cared for and receive treatment for their cancer.
Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study Clinical Cancer Research, Online ahead of print.
Read More

Herbst RS, Kuriki H, Spigel DR (2021)
Read More

Zhao J, Lu L (2021)
Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival Recent Patents on Anti-Cancer Drug Discovery, Online ahead of print.
Read More

Suhail Y, Afzal J, Kshitziz (2021)
Read More

Neoadjuvant Durvalumab Plus Weekly Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Triple-negative Breast Cancer NPJ Breast Cancer.
Read More

A Stakeholder-Driven Qualitative Study to Define High Quality End-of-Life Care for Children with Cancer Journal of Pain and Symptom Management, Online ahead of print.
Read More

Montanari F, Orjuela-Grimm M (2021)
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra Current Hematologic Malignancy Reports, Online ahead of print Read More

Targeted RNAseq Assay Incorporating Unique Molecular Watch Now

Watch Now

Follow Yale Cancer Center on Twitter

"Cancer and Covid-19 may be distinctly different maladies, but there are fundamental similarities in the lived experiences of their #survivors. The more the two communities can learn from and support one another, the better."

Register to join .@dcmadoff & @MarioStrazzabos Thursday, February 25th at 6pm for a virtual CME series SmilowCancer #LiverCancer program to discuss "Locoregional Therapies for Liver Tumors: 2021 Update"

Want to discuss Cell Therapy & Transplantation? Join Drs. Lohith Gowda & Iris Isufi Friday, February 19th at Noon for @YaleCancer virtual #ASH20 Highlights CME series presented by @YaleHematology

We're very pleased to announce .@maryam_lustberg has been named Director of The Breast Center @SmilowCancer Hospital and Chief of Breast Medical Oncology @YaleCancer.

"We need future trials to better understand body composition changes to develop interventions to reduce declines in muscle mass."
@mirwin_yale on findings in @JNCCN showing weight loss associated w/worse #breastcancer outcomes.

Join us today at noon for .@YaleCancer virtual Grand Rounds. @CharlesFuchsMD will be discussing the State of Yale Cancer Center and @SmilowCancer.

Congratulations to Dr. Valentina Greco on receiving the 2021 Momentum Award from the @ISSCR for her stem cell-related research and trajectory for future success.

Encouraging news in the battle against #BladderCancer! New research led by
Targeted RNAseq Assay Incorporating Unique Molecular Identifiers for Improved Quantification of Gene Expression Signatures and Transcribed Mutation Fraction in Fixed Tumor Samples

*BMCCancer.*

PON2 Subverts Metabolic Gatekeeper Functions in B Cells to Promote Leukemogenesis

*Proceedings of the National Academy of Sciences.*


Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology

*JCO Global Oncology.*

Funding and Award Opportunities

**Fund to Retain Clinical Scientists at the Yale School of Medicine (FRCS)**
Made possible by a grant from the Doris Duke Charitable Foundation and funding from the Yale School of Medicine, the FRCS program provides supplemental research support to early-career physician-scientists and scientists who face significant caregiving demands. The goal of the program is to retain such scientists in the research enterprise.

**Application Deadline:** February 25, 2021

Read More

**ASTRO Residents/Fellows in Radiation Oncology Biology Seed Grant**
This grant is designed to fund novel projects, and support residents or fellows who are interested in radiation-oncology related basic science, or clinical research.

**Application Deadline:** February 26, 2021

Read More

**ASTRO Residents/Fellows in Radiation Oncology Seed Grant**
This grant is designed to fund novel projects, and support residents or fellows performing biological research in radiation oncology and/or cancer focused sciences.

**Application Deadline:** February 26, 2021

Read More

**ASTRO-AAPM Physics Residents/Postdoctoral Fellows Seed Grant**

Calendar

**Yale ASH 2020 Highlights**
February 19; 12:00 PM
*Cell Therapy and Transplantation*
Lohith Gowda, MD, MRCP & Iris Isufi, MD
Learn More

**Developmental Therapeutics Research Program Seminar**
February 19, 1:00 PM
*New Paradigms in Therapeutic Action*
David Spiegel, PhD
Learn More

**YCCEEH Seminar**
February 19; 2:00 PM
*Cell Fate Decisions in Hematopoiesis*
Marjorie Brand, PhD
Learn More
Grant
This grant is a joint effort to advance the field of radiation oncology through the support of talented early-career scientists performing physics and radiation oncology-related research. The aim of this grant is to support the next generation of researchers.
Application Deadline: February 26, 2021
Read More

ASTRO-BCRF Career Development Award to Cure Breast Cancer
The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for breast cancer patients.
Application Deadline: February 26, 2021
Read More

ASTRO-PCF Career Development Award to End Prostate Cancer
The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for prostate cancer patients.
Application Deadline: February 26, 2021
Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)
The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions.
Application Deadline: February 26, 2021
Read More

Dissertation Presentation
February 22; 3:00 PM
Delving into Survival of Colorectal Cancer - Long-term Survival, Younger Populations, and Prediction Models
En Cheng
Learn More

MB&B Special Seminar
February 22; 4:00 PM
Proteolytic Regulation of Pyroptosis
Dr. C. Taabazuing
Learn More

Yale Cancer Center Grand Rounds
February 23; 12:00 PM
Translational Science in Hematologic Malignancies
Stephanie Halene, MD, PhD | Francine Foss, MD | Thomas Prebet, MD, PhD | Natalia Neparidze, MD
Learn More

Monthly Palliative Care Conference
February 23; 4:00 PM
A Comparison of Hospitalized Patients With Heart Failure and Cancer Referred to Palliative Care
DeLuca Awards
The DeLuca Center for Innovation in Hematology Research was formed thanks to a generous donation by the Frederick A. DeLuca Foundation. Each year a total of 5 Pilot Awards and 1 Career Development Award will be awarded to investigators who are participating in hematologic based research.

Career Development Award: intended to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes.
Letter of Intent Due: March 1, 2021

JH Milstone Fund 2021
This FOA supports early stage investigators and innovative research and education in thrombosis, thrombolysis and hemostasis. Proposals may focus on any aspect of thrombosis, thrombolysis and hemostasis – including biochemistry, genetics, clinical evaluation and testing, quality improvement and treatment. Please contact Richard Carr for more information.
Letter of Intent Due: March 1, 2021

The Mark Foundation Endeavor Awards
These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.
Application Deadline: March 1, 2021

International Research Scientist Development Award (IRSDA) (K01)
The purpose of this Award is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty for an intensive, mentored research career development experience in a low- or middle-income country leading to an independently-funded research career focused on global health.
Application Deadline: March 9, 2021

Department of Defense (DoD) Breast Cancer Awards
- Breast Cancer, Breakthrough Award Levels 1 and 2 - Application Deadline: March 11, 2021, Read More
- Breast Cancer, Era of Hope Scholar Award - Application Deadline: March 11, 2021, Read More
- Breast Cancer, Transformative Breast Cancer Consortium Award - Application Deadline: March 12, 2021, Read More
- Breast Cancer, Innovator Award - Application Deadline: March 12, 2021, Read More

Human and Translational Immunology Seminar Series
February 23; 4:00 PM
The ABCs of Autoimmunity
Alessandra Pernis, MD
Learn More

Take Care Tuesdays
February 23; 6:30 PM
Covid, Cancer and Self-Care!
Elena Ratner, MD | Shantana Hazel | Susan Hess, MA
Learn More

Therapeutic Radiology Grand Rounds
February 25; 9:00 AM
MRI Guided Adaptive Radiotherapy
Ben Slotman, MD, PhD, FASTRO, H.FACR
Learn More

Palliative Care and Symptom Science (PASS) Seminar
February 25; 12:00 PM
Anne Black, PhD & William Becker, MD
Learn More

Pathology Grand Rounds
February 25; 12:30 PM
The Genetics of Recurrent Hydatidiform Moles
Rima Slim, MSc, PhD
Learn More

Cancer Genetics and Prevention Seminar
February 25; 2:30 PM
Learn More

Center for GI Cancers Weekly Seminar
February 25; 4:15 PM
GI ASCO Review
- Breast Cancer, Breakthrough Award Level 3 - Application Deadline: March 12, 2021, Read More

- Breast Cancer, Breakthrough Award Level 4 - Application Deadline: March 12, 2021, Read More

Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01)
The purpose of this FOA is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations.
**Application Deadline:** March 15, 2021
Read More

Breast Cancer Alliance Exceptional Project Grants
The BCA invites clinical doctors and research scientists at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. This award recognizes creative, unique, and innovative research and is open to applicants throughout the US.
**Internal LOI Deadline:** March 17, 2021
Read More

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery
This FOA invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing.
**Application Deadline:** March 17, 2021
Read More

Cellular Cancer Biology Imaging Research (CCBIR) Program (U54)
The NCI invites applications for Cellular Cancer Biology Imaging Research (CCBIR) Centers. The Centers will develop and test enabling imaging technologies at the cellular and organ scales driven by specific fundamental questions in cancer biology. The overall purpose of the CCBIR initiative is to facilitate innovation in advanced imaging technologies that could be applied to fundamental basic and pre-clinical research problems in cancer biology.
**Application Deadline:** March 18, 2021
Read More

Alex's Lemonade Stand 2021 Reach Grant
The purpose of the Reach Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic.
**Application Deadline:** March 22, 2021
Read More

American Cancer Society Research Scholar Grants
The RSG supports investigator-initiated projects across the cancer research continuum. Independent investigators in the first 8 years of an independent research career or faculty appointment are eligible to apply.
**Application Deadline:** April 1, 2021
Read More

Yale Liver Tumor Lectures: A CME Series Presented by the Smilow Liver Cancer Program
**February 25; 6:00 PM**
Locoregional Therapies for Liver Tumors: 2021 Update
David C. Madoff, MD
Learn More

Yale Cancer Answers
**February 28; 7:30 PM**
NPR
Experimental Therapeutics
Patricia LoRusso, DO
Learn More

Center for Methods in Implementation and Prevention Science (CMIPS) Seminar Series
**March 1; 2:00 PM**
Terry Huang, PhD
Learn More

Yale Center for Immuno-Oncology Seminar Series
**March 2; 4:00 PM**
Antoni Ribas, MD, PhD
Learn More

Pathology Grand Rounds
**March 4; 12:30 PM**
How Twitter & Facebook Changed my Life: The Role of Social Media in Pathology & Medicine
Jerad Gardner, MD
Learn More

Cancer Genetics and Prevention Seminar
**March 4; 2:30 PM**
Learn More

Center for GI Cancers Weekly Seminar
**March 4; 4:15 PM**
Sajid A Khan, MD, FACS, FSSO
Learn More
NCCN Request for Proposals (RFP): Phase I/II Clinical and/or Correlative Studies of the panHER Inhibitor Neratinib in the Treatment of Breast, Gastrointestinal, Lung, and Neurological Cancers
This RFP is to support NCCN Member Institution faculty for the performance of clinical and correlative studies to further evaluate the effectiveness of neratinib in the treatment of breast, gastrointestinal (GI), lung and neurological cancers.
**Application Deadline:** April 19, 2021

Cancer Grand Challenges Program
The NCI and Cancer Research UK (CRUK) are partnering to fund the Cancer Grand Challenges program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer. These nine challenges are aimed at solving complex problems in cancer research, which, if solved, could have a transformative impact towards progress.
**Application Deadline:** April 22, 2021

Submissions
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications